van der Meer 2018.

Study characteristics
Methods	Participants randomly assigned to intervention or control group. Randomisation process was conducted by the principal investigator, who was not involved in recruitment or data collection.
Participants	Sample size: 164 Setting: 15 community pharmacies in Northern Netherlands Time frame for trial recruitment: December 2014–October 2015 Inclusion criteria Community‐based patients living independently Age ≥ 65 years Use of ≥ 5 medications for ≥ 3 months, including ≥ 1 psycholeptic or psychoanaleptic medication (ATC code N05 or N06) DBI ≥ 1 Exclusion criteria Limited life expectancy (< 3 months) Non‐Dutch language speakers Advanced dementia Medication review within the past 9 months before the study period Urgent need for medication review Baseline characteristics Age: mean 76 years Sex: 111/157 female Baseline DBI: mean 3.1–3.2 Proportion with/without cognitive impairment not reported Mean number of medicines: 8.4 in intervention group, 9.3 in control group) % with high education: 12% in intervention group, 15.8% in control group % with no/low/medium education: 77.3% in intervention group, 78% in control group
Interventions	Intervention: anticholinergic burden reduction aimed at achieving 0.5‐point reduction in DBI via medication 'optimisation'. Pharmacist‐led medication review (in communication with GP). A 5‐step medication review took place within days after the baseline measurement, as follows. Step 1: face‐to‐face consultation between the pharmacist and participant to discuss medication use Step 2: pharmacist undertook a medication review and drafted recommendations for medicine optimisation to the participant's GP Step 3: multidisciplinary meeting between pharmacist and GP to discuss participant's medications and draft and action plan Step 4: draft action plan discussed between participant, pharmacist, and GP, and any necessary alterations made, factoring in participant's wishes Step 5: follow‐up of the action plan Control: usual care
Outcomes	Seven Minute Screen (7MS) Trail Making Test (TMT) A & B Digit Symbol Substitution Test (DSST) Follow‐up: 3 months
Notes

ADS: Anticholinergic Drug Scale; ATC: Anatomic Therapeutic Classification; CCI: Charlson Comorbidity Index; CERAD: Consortium to Establish a Registry for Alzheimer's Disease; DBI: drug burden index; GP: general practitioner; MMSE: Mini‐Mental State Examination; PRN: pro re nata (as needed).